west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "免疫治疗" 101 results
  • Dust Mite Sublingual Immunotherapy for Allergic Rhinitis: A Meta-Analysis

    Objective To assess the effectiveness of dust mite sublingual immunotherapy (SLIT) for treating allergic rhinitis. Methods The randomized controlled trials (RCTs) about SLIT treating allergic rhinitis were collected in MEDLINE, EMbase, The Cochrane library (Issue 10, 2012), CNKI, VIP, WanFang Data and CBM from inception to October, 2012. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the quality, and then the meta-analysis was performed by using RevMan 5.1 software. Results A total of 8 RCTs involving 788 patients were included. The results of meta-analysis showed that, compared with the control group, SLIT showed no obvious difference in the total effective rate (RR=1.15, 95%CI 0.88 to 1.50, P=0.29), but it was superior in decreasing the scores of both nasal symptom (SMD= −1.13, 95%CI −2.07 to −0.20, P=0.02) and drug intake (SMD= −0.60, 95%CI −1.06 to −0.15, P=0.009). Conclusion SLIT can improve the symptoms of patients with allergic rhinitis, and it can also decrease the using frequency of antihistamine, beta-blocker and nasal spray steroids.

    Release date: Export PDF Favorites Scan
  • Methodological evaluation of clinical research literatures forregulating the immune function of COPD

    Objective To assess the quality of randomized controlled trials (RCTs) and clinical controlled trials (CCTs) relevant to COPD besides chronic bronchitis and chronic pulmonary cor disease in strengthening immune published in Chinese medical journals to provide scientific basis of systematic review (SR) of regulating the immune function of COPD in Chinese herbs. Methods 54 articles with clinical controlled trials were obtained by electronic searching and handsearching, and the method for randomized allocation, blindness, multi-centres, sample sizes, diagnosis criteria, exclusion criteria, source of cases, immune markers (cellular immunity, humoral immunity, erythrocyte immunity, nonspecific immunity), the clinical outcome assessment, statistical management, course of treatment and the side effects or adverse drag reaction, follow-up were investigated and then methodologically evaluated. According to the investigation, literatures with the method for randomized allocation, correct controls, appropriate sample sizes (≥60), the nation-wide diagnosis criteria, the objective clinical outcome assessment distinct statistical method were stipulated as the high-quality ones relatively. Results Among the 54 trials, 70.4% had explicit diagnosis criteria, 18.5% with exclusion criteria, 20.4% with comparability of baseline, 37.0% with distinct statistical method. In the therapy, 63.0% were with Chinese herbs. Conclusion The selected 7 articles belong to the high quality and possibly are to be explored in Meta-analysis.

    Release date:2016-08-25 03:16 Export PDF Favorites Scan
  • 多发性骨髓瘤过继细胞免疫治疗的研究进展

    【摘要】 多发性骨髓瘤(multiple myeloma, MM)是严重威胁健康的恶性浆细胞疾病,主要的治疗方法是传统化学疗法,但其疗效有限,患者生活质量低,预后差。免疫治疗是一种新兴的有望在未来彻底消灭肿瘤细胞的治疗手段,过继细胞免疫治疗(adoptive cellular immunotherapy, ACI)更是经体内及体外都证实了具有强大的抗瘤作用。ACI与其他治疗手段的有机结合和合理安排将对MM的治疗带来新的曙光。现就目前开展的ACI治疗MM的前沿研究予以综述。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • Anti-Colon Cancer Immunity of Whole Cell Lysates Pulsed Dendritic Cell

    Objective To detect the anti-colon cancer ability of whole cell lysates pulsed dendritic cell (DC) which acts as an adjuvant. Methods Whole cell lysates of LoVo cells were extracted with freeze thawing method, then the monocyte-derived DC were pulsed with this cellular antigen. Subsequently, the capability of antigen pulsed DC to promote T lymphocytes proliferation and the ability of T lymphocytes to kill LoVo cells were detected by 3H-TdR incorporation and lactate dehydrogenase release methods, respectively. Results The whole cell lysates of LoVo cells pulsed DC significantly stimulated T cells proliferation, and the cytotoxicity abilities of primed T cells to kill LoVo cells were also enhanced. Conclusion Tumor cell lysates which act as the cellular antigen to pulse DC can improve the efficacy of anti-cancer immune response, which provides us an experimental evidence for cancer immunotherapy.

    Release date:2016-08-28 03:48 Export PDF Favorites Scan
  • Immunological Treatment for Sepsis and Septic Shock

    Release date:2016-08-28 04:43 Export PDF Favorites Scan
  • ADVANCES AND PROBLEM IN IMMUNOTHERAPY OF BREAST CARCINOMA

    众所周知,机体存在免疫监视和抗肿瘤免疫功能,是防止肿瘤发生、发展的天然屏障,乳腺癌的发生说明机体免疫系统的监视作用已经失效,乳腺癌的发展提示机体自身的抗肿瘤免疫已不足以阻止肿瘤的生长,这一事实提示人们,在机体发生恶性肿瘤时,自身的防御机能减弱或受到抑制。因此,临床工作者一直不懈努力,探索各种用免疫学原理和技术治疗乳腺癌的方法,以提高临床治疗效果。随着科学技术的发展和进步,有关乳腺癌免疫治疗的基础和临床应用研究发展很快,成为基础研究和临床结合紧密的成功范例之一。各种新的理论、新的技术不断涌现,最新的实验研究成果快速引入临床实践,在很多方面已有明显的突破。目前,乳腺癌的免疫治疗已成为继手术治疗、放射治疗、化疗和内分泌治疗以外的新的有效治疗手段,并将随着研究的深入而起到越来越重要的作用。

    Release date:2016-08-28 05:11 Export PDF Favorites Scan
  • The Effect of CD3AK Cells on T Lymphocyte Subsets and Its Functions of Patients with Primary Liver Carcinoma

    Objective To explore the effect of CD3AK cells on T lymphocyte subsets and its functions of patients with primary liver carcinoma (PLC). MethodsFiftyeight patients with PLC were divided into two groups, CD3AK group (n=37), control group (n=21). Eleven blood donors were taken as normal control. All patients from the treatment group were given 2×109 CD3AK cells once a day for 5 days on the 1st day after operation, having received IL2 at a dose of 100 units per 24 hour by intravenous injection starting 30 minutes before administration of CD3AK cells. T lymphocyte subsets, IL2R, NK activity, LAK activity and proliferative activity were determined. ResultsThe CD4/CD8 ratio, expression of IL2R, proliferative activity, NK activity and LAK activity of T lymphocytes from the treatment group were significantly higher than those of control respectively.Conclusion The adoptive transfer of CD3AK cells could improve the disorder of T lymphocyte subsets and its functions and provide the patients with PLC with fresh abundant effectors against tumor.

    Release date:2016-08-28 05:11 Export PDF Favorites Scan
  • A REPORT ON THE TREATMENT OF PATIENTS WITH ADVANCED PRIMARY LIVER CANCER USING INTERLEUKIN-2 AND LYPHOKINE ACTIVATED KILLER CELLS COMVINED WITH SURGERY OR CHMOTHERAPY

    31 case of advanced primary liver cancer were treated by using IL-2 and LAK cells in which 15 cases were combined with surgery (group A) and 16 cases were combined with chemotherpy (Group B). 7~14 months follow-up showed: In group A there was no recurence and metastasis, and the cell-mediated immunity was obviously improved. In group B, the average life time was more than 5.84 months, the tumor average diameter dicreased in 10 cases ,and the cee-mediated immunity was also improved. The role of immunotherapy combined with surgery or chemotherapy was discussed.

    Release date:2016-08-29 04:26 Export PDF Favorites Scan
  • Allergen specific sublingual immunotherapy

    变应原特异性免疫治疗(SIT)是目前已知的唯一能改变变态反应性疾病患者对变应原免疫的类型,并有可能治愈变态反应性疾病的方法。通常是通过反复多次皮下注射,即皮下免疫治疗(SCIT),诱导患者对变应原的耐受,但因其不良反应较大,并有可能引起过敏性休克等原因而使其应用受到限制。近来通过舌下含服的方法进行免疫治疗,即舌下免疫治疗(SLIT),引起了临床上广泛的兴趣。与SCIT相比,SLIT完全由患者自己使用药物,因此更方便,临床研究也证实这种方法更安全,也更有效。而且与药物治疗相比,SLIT可以显著降低临床费用,减轻患者和社会的负担。但是SLIT诱导免疫耐受的确切机制目前仍不清楚。

    Release date:2016-08-30 11:37 Export PDF Favorites Scan
  • Efficacy of Specific Immunotherapy Combined with Budesonide Formoterol Dry Powder Inhaler for Treatment of Moderate to Severe Asthma

    Objective To evaluate the efficacy of specific immunotherapy in combination with budesonide formoterol dry powder inhaler ( BUD/FM) in the treatment of moderate to severe bronchial asthma. Methods The data of 93 patients with moderate to severe asthma from September 2006 to September 2008 were analyzed. 46 cases who received BUD/FM therapy were recorded as a BUD/FM treatment group, and 47 cases who received BUD/FMand dustmite specific immunotherapy were recorded asa combination treatment group. After 6, 12, 18, and 24 months, asthma symptom scores, pulmonary function,effective rate, and scores of Asthma Quality of Life Questionnaire ( AQLQ) were compared in the two treatment groups. Results Compared with the BUD/FMtreatment group, the effective rate was significantlyhigher ( 83. 0% vs. 65. 2% , P lt;0. 05) , the lung function improvements in FEV1% pred and expiratory peak flow were more significant in the latter period of treatment, and AQLQ scores improved more significantly after 24 months’treatment in the combination treatment group. Conclusion For patients with moderate tosevere asthma, specific immunotherapy in combination with BUD/FMcan improve asthma symptoms and lung function with good compliance and long lasting efficacy.

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
11 pages Previous 1 2 3 ... 11 Next

Format

Content